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INTRODUCTION 
Viral hepatitis is liver inflammation due to viral infection. Several 
viruses can cause liver inflammation, including hepatotropic virus-
es, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, and 
so on. The most common causes of viral hepatitis are hepato-
tropic viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), 
hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E vi-
rus (HEV). These five hepatitis viruses are very different in their 
modes of transmission and health outcomes (Table 1). Viral hepa-
titis, particularly hepatitis B and hepatitis C, has been silent killer 
for decades across all global regions.1 An estimated 1.4 million 
deaths per year are caused by acute infection and hepatitis-relat-
ed liver cancer and cirrhosis. Of those deaths, approximately 47% 
are attributable to HBV, 48% are due to HCV, and the remainder 
is due to HAV and HEV. Worldwide, approximately 240 million 
people have chronic HBV infections and 130-150 million have 
chronic HCV infections. Unlike most other communicable diseas-
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es, absolute burden and relative rank of viral hepatitis were in-
creased between 1990 and 2013.2 Without expanded and accel-
erated response, viral hepatitis will be a huge burden for the next 
40-50 years, with cumulative deaths estimated to be approxi-
mately 20 million between 2015 and 2030.3 Viral hepatitis is 
gaining greater attention nowadays with some vital progress 
made.1 Transmission of hepatitis B virus can be blocked by vacci-
nation. Progression of hepatitis B virus-related liver disease can 
be prevented by long-term viral suppression with effective drugs.4 
Oral direct antiviral agents against hepatitis C virus have been de-
veloped. These drugs are highly effective in eradicating hepatitis 
C virus and well-tolerated by patients.5 During World Health As-
sembly held in May 2016, World Health Organization (WHO)’s 
Global Strategy for Viral Hepatitis was approved. It elevated hepa-
titis to a higher priority with a goal to eliminate viral hepatitis as a 
public health threat by 2030. Its vision is that viral hepatitis trans-
mission is halted in the world and everyone living with viral hepa-
titis has access to safe, affordable, and effective care and treat-
ment.3 
VIRAL HEPATITIS: HEPATITIS A
Hepatitis A is a liver disease caused by HAV.6 Hepatitis A is pri-
marily spread when an uninfected (and unvaccinated) person in-
gests food or water that is contaminated with feces of an infected 
person.7 The disease is closely associated with unsafe water or 
food, inadequate sanitation, and poor personal hygiene. HAV is 
one of the most frequent causes of foodborne infections. Epidem-
ics related to contaminated food or water can erupt explosively.8,9 
Geographical distribution areas of hepatitis A can be character-
ized as having high, intermediate, or low levels of HAV infection.7 
In developing countries with poor sanitary conditions and hygienic 
practices, most (90%) children have been infected by HAV before 
the age of 10 years. Those infected during childhood do not expe-
rience any noticeable symptoms. Epidemics are uncommon be-
cause older children and adults are generally immune. Symptom-
atic disease rates in these areas are low and outbreaks are rare. 
In developing countries, countries with transitional economies, 
and regions where sanitary conditions are improved, children can 
often escape infections in early childhood and reach adulthood 
without immunity. Ironically, improved economic and sanitary 
conditions may lead to accumulation of adults who have never 
been infected, and  have no immunity.10 Higher susceptibility in 
older age group may lead to higher symptomatic disease rates 
and large outbreaks in these communities. In developed countries 
with good sanitary and hygienic conditions, infection rates are low. 
Disease may occur among adolescents and adults in high-risk 
groups such as people travelling to areas with high endemicity.
Symptoms of hepatitis A range from mild to severe. Adults have 
signs and symptoms of illness more often than children.6 Severity 
of the disease and fatal outcomes are higher in older age groups. 
Hepatitis A infection does not cause chronic liver disease. Howev-
er, it can cause acute liver failure. Acute hepatitis A can be diag-
nosed by the detection of hepatitis A virus-specific immunoglobu-
lin M antibodies in the blood. Those who have recovered from 
hepatitis A infection and those who are vaccinated will show hep-
atitis A virus-specific immunoglobulin G antibodies in the blood. 
There is no specific treatment for hepatitis A. Recovery from 
symptoms following infection may be slow. It may take several 
weeks or several months. Hepatitis A can be prevented by improv-
ing sanitation and food safety. It can also be prevented by immu-
nization.7
HEPATITIS B
Hepatitis B is a liver infection caused by HBV.4 It can cause 
Table 1. Characteristics of hepatotrophic viruses 
Hepatitis A virus Hepatitis B virus Hepatitis C virus Hepatitis D virus Hepatitis E virus
Genome RNA DNA RNA RNA RNA
Family Picorna viriade Hepadna viridae Flavi viridae Deltavirus Hepa viriade
Incubation (d) 15-45 30-180 15-150 30-180 15-60
Transmission Fecal to Oral Blood Blood Blood Fecal to Oral
Chronicity No Yes Yes Yes Rare
Prevention Vaccine Vaccine No HBV vaccine Vaccine*
Antivirals drugs No Yes Yes Yes No
*Approved in China only. 
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chronic infection. It is a major cause of liver cirrhosis and liver 
cancer for those who are chronically infected.4 Hepatitis B preva-
lence is different according to geographic regions. High rates of 
chronic infections have been found in sub-Saharan Africa, East 
Asia, Amazon area, and southern parts of eastern and central Eu-
rope.7 In highly endemic areas, hepatitis B is most commonly 
spread through mother-to-child transmission.11 Chronic infection 
is very common when infected in infant period or before the age 
of 5 years. Hepatitis B can also spread through percutaneous or 
mucosal exposure to infected blood and various body fluids. 
Transmission of the virus may also occur through sexual contact, 
reuse of needles and syringes during medical, surgical, and dental 
procedures, tattooing, or use of razors and similar objects that are 
contaminated with infected blood. Infection that develops in 
adulthood can lead to chronic hepatitis in less than 5% of cases. 
Most people do not experience any symptoms during the acute 
infection phase. A small subset of people with acute hepatitis can 
develop acute liver failure which can lead to death. When it 
causes chronic liver infection, it can lead to liver cirrhosis and liver 
cancer.4
Hepatitis B can be diagnosed by detecting hepatitis B surface 
antigen. Acute or chronic infection can be differentiated by per-
forming immunoglobulin antibody to core antigen and hepatitis B 
e antigen. Virus can be detected by performing polymerase chain 
reaction (PCR). No specific treatment can completely eradicate 
hepatitis B virus. However, oral nucleos(t)ide analogue has been 
developed. It can effectively suppress hepatitis B replication. In-
terferon can also be used to suppress hepatitis B replication in 
highly selected setting.4
Hepatitis B transmission can be prevented by using hepatitis B 
vaccine. In addition, implementing blood safety strategies, includ-
ing quality-assured screening of all donated blood and blood com-
ponents used for transfusion, safe injection practices, and safe sex 
practices can prevent the transmission of hepatitis B virus.4 
HEPATITIS C
Hepatitis C virus causes both acute and chronic infections.5 
Acute infection is usually asymptomatic. About 15–45% of infect-
ed persons can spontaneously clear the virus within 6 months of 
infection without any treatment. The remaining 55–85% of per-
sons will develop chronic HCV infection. Of those with chronic 
HCV infection, some will develop liver cirrhosis and liver cancer. 
HCV is found worldwide. The most affected regions are Africa, 
Central Asia, and East Asia. Depending on the country, hepatitis 
C infection can be concentrated in certain populations (for exam-
ple, among people who inject drugs). HCV is a bloodborne virus. 
It can be transmitted through contaminated injection equipment, 
reuse or inadequate sterilization of medical equipment (syringes 
and needles in healthcare settings), and transfusion of unscreened 
blood or blood product. HCV can also be transmitted sexually.4  
HCV can be confirmed by PCR detection of the virus. As PCR 
analysis is costly, anti-hepatitis C virus antibody is usually per-
formed to screen those who might have been infected with the vi-
rus. Treatment for hepatitis C is changing rapidly. Recently, direct 
antiviral agents have been developed. They are highly effective, 
safe, and better-tolerated by patients. Therapy with direct antiviral 
agents can cure almost all infected persons in a short (usually 12 
weeks) duration. Since there is no vaccine for hepatitis C, preven-
tion of HCV infection depends upon reducing the risk of exposure 
to the virus (in health-care settings, in higher risk populations such 
as people who inject drugs, or through sexual contact).5,7
HEPATITIS D
Hepatitis D is a liver disease caused by HDV.7,12 HDV requires 
HBV for its replication. Hence, Hepatitis D infection cannot occur 
in the absence of HBV. Coinfection or super infection of HDV with 
HBV causes more severe disease than HBV mono-infection. It is 
estimated that 5% of hepatitis B surface antigen positive people 
are coinfected with HDV globally. Distribution of HDV is world-
wide. However, its prevalence is different according to region. 
High-prevalence areas include the Mediterranean, Middle East, 
Pakistan, Central Asia, and Northern Asia. Its prevalence is low in 
North America, Northern Europe, South Africa, and East Asia in-
cluding South Korea.13
HDV can be diagnosed by finding antibody against HDV. It can 
be confirmed by detection of HDV RNA in serum. However, HDV 
diagnostics are not widely available. There is no standardization 
for HDV RNA assay. There is no specific treatment for acute or 
chronic HDV infection either. Persistent HDV replication is the 
most important predictor of mortality and the need for antiviral 
therapy. Pegylated interferon alpha is the only drug effective 
against HDV. Antiviral nucleotide analogues for HBV have no or 
limited effect on HDV replication. Prevention and control of HDV 
infection requires prevention of HBV transmission through hepati-
tis B immunization, blood safety, injection safety, and harm-re-
duction services.12 
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HEPATITIS E
Hepatitis E is a liver disease caused by HEV. HEV is a small RNA 
virus with a positive-sense and single-stranded RNA genome.14 
The virus has at least 4 different types: genotypes 1, 2, 3, and 4. 
Genotypes 1 and 2 have only been found in humans. Genotype 3 
and 4 viruses circulate in several animals, including pigs, wild 
boars, and deer without causing any disease. They occasionally 
infect humans. The virus is shed into stools of infected persons. It 
then enters human body through the intestine. It is transmitted 
mainly through contaminated drinking water. Usually the infection 
is self-limiting. It will resolves within 2–6 weeks. Occasionally, 
acute liver failure will develop which can lead to mortality. Fulmi-
nant hepatitis occurs more frequently when hepatitis E occurs 
during pregnancy. For immune comprised people, HEV is known 
to cause chronic infection.7,14 
Hepatitis E infection is found worldwide. This disease is com-
mon in resource-limited countries with limited access to essential 
water, sanitation, hygiene, and health services. In these areas, 
this disease occurs both as outbreaks and as sporadic cases.15 
Outbreaks usually follow periods of fecal contamination of drink-
ing water supplies. It might affect several hundred to several 
thousand people. In these areas, an estimated 20 million infec-
tions and 3.3 million acute cases occur annually worldwide, with 
an estimated 56,600 deaths.7,15 In areas with better sanitation 
and water supply, hepatitis E disease is infrequent with only occa-
sional sporadic cases.16 Most of these cases are caused by geno-
type 3 virus. These cases are caused by infection with virus origi-
nating from animals, usually through ingestion of undercooked 
animal meat, including animal liver. They are not related to con-
tamination of water or other foods.7 
Definitive diagnosis of hepatitis E infection is usually based on 
the detection of specific antibodies to HEV. Additional tests in-
clude PCR detection of HEV RNA in blood and/or stool. There is 
no specific treatment capable of altering the course of acute hep-
atitis E. Immunosuppressed people with chronic hepatitis E might 
benefit from specific treatment using ribavirin. A recombinant 
subunit vaccine to prevent HEV infection has been registered in 
China. However, it has not been approved in other countries 
yet.7,17 
WHO STRATEGY FOR VIRAL HEPATITIS CONTROL
WHO has stated that ending viral hepatitis epidemics as a major 
public health threat is feasible with tools and approaches currently 
available and those in the pipeline (Table 2). Interventions include 
vaccines, prevention of mother-to-child transmission of HBV, injec-
tion safety, blood and surgical safety, harm reduction for people 
who inject drugs, and drug treatments. To control viral hepatitis, a 
continuum of hepatitis services are needed, including reducing vul-
nerability, preventing and diagnosing infection, linking people to 
health services, and providing treatment and chronic care (Fig. 1). 
The goal of WHO is to achieve 90% reduction for new cases of 
chronic hepatitis B and C infection and 65% reduction for mortality 
from viral hepatitis. To achieve such goal, WHO has set seven ser-
vice coverage targets that need to be achieved (Table 3). WHO urg-
es countries to develop practicable ambitious national goals and 
targets by taking country context into consideration, including the 
nature and dynamics of country viral hepatitis epidemics, popula-
tions affected, structure and capacity of the health care and com-
munity systems, and resources that can be mobilized. 
Table 2. WHO interventions
Interventions Comment
Vaccines Effective vaccines are available for preventing HAV, HBV and HEV*
Prevention of mother-to-child 
transmission of HBV
Antenatal testing, the use of antiviral drugs, and timely HBV birth-dose vaccination
Injection, blood and surgical 
safety
Universal precautions for all invasive medical interventions, promotion of injection safety measures, 
securing the safe supply of blood products
Harm reduction for people who 
inject drugs
Ensuring access to sterile injecting equipment and effective drug dependence treatment
Treatment Antiviral drugs for HBV and HCV. New oral, well-tolerated medicines for HCV with a cure rates of over 90%. 
Oral, well-tolerated medicines for HBV which can effectively suppress viral replication, although this 
treatments needs to be lifelong
*Approved in China only. 
HAV, hepatitis A virus; HBV, hepatitis B virus; HEV, hepatitis E virus; HCV, hepatitis C virus.
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Table 3. WHO targets 
TARGET AREA 2020 TARGETS 2030 TARGETS
Incidence: New cases of chronic viral hepatitis B 
and C infections
30% reduction (equivalent to 1% 
prevalence of HBsAg among children)
90% reduction (equivalent to 0.1% 
prevalence of HBsAg among children)
Mortality: Viral hepatitis B and C deaths 10% reduction 65% reduction
Hepatitis B virus vaccination: childhood vaccine 
coverage (third dose coverage) 
90% 90%
Prevention of hepatitis B virus mother-to-child 
transmission: hepatitis B virus birth-dose 
vaccination coverage or other approach to 
prevent mother-to-child transmission
50% 90%
Blood safety 95% of donations screened in a quality 
assured manner
100% of donations are screened in a 
quality assured manner
Safe injections: percentage of injections 
administered with safety-engineered devices in 
and out of health facilities
50% 90%
Harm reduction: number of sterile needles and 
syringes provided per person who injects drugs 
per year
200 300
Viral hepatitis B and C diagnosis 30% 90%
Viral hepatitis B and C treatment 5 million people will be receiving 
hepatitis B virus treatment
3 million people have received hepatitis 
C virus treatment
80% of eligible persons with chronic 
hepatitis B virus infection treated
80% of eligible persons with chronic 
hepatitis C virus infection treated
GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS, 2016–2021 19
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THE CONTINUUM OF HEPATITIS SERVICES –  
AN ORGANIZING FRAMEWORK
 PUBLIC HEALTH APPROACH
While the concept of universal health coverage frames  
the strategy overall, the continuum of hepatitis services 
that are needed to curb the epidemic provides the 
organizing framework for the specific actions to be taken 
(see Figure 5). That continuum spans the entire range of 
interventions that is needed to achieve the strategy’s targets 
– from reducing vulnerability, preventing and diagnosing 
infection, linking people to health services, through  
to providing treatment and chronic care. The strategy 
defines the essential services and interventions that need 
to be delivered along this continuum and the strategic 
information that is needed to focus interventions for 
maximum impact.
The strategy is based on a public health approach that is concerned with  
preventing infection and disease, promoting health, and prolonging life  
among the population as a whole. It aims to ensure the widest possible access 
to high-quality services at the population level, based on simplified and 
standardized interventions and services that can readily be taken to scale  
and decentralized, including in resource-limited settings. A public health 
approach aims to achieve health equity and promote gender equality,  
engage communities, and leverage public and private sectors in the response.
Figure 5. The continuum of viral hepatitis services and the retention cascade
Figure 1. The continuum of viral hepatitis services and the retention cascade (Adopted from GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 
2016–2021).
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CURRENT STATUS AND STRATEGIES FOR  
VIRAL HEPATITIS CONTROL IN SOUTH KOREA
In South Korea, liver disease is a huge public health burden. In 
2015, liver disease was the 8th leading cause of mortality, with 
13.4 deaths per 100,000 persons. Moreover, liver cancer is the 2nd 
leading cause of mortality, with 22.2 deaths per 100,000 persons. 
Most (70-80%) liver cancers in South Korea are attributable to 
hepatitis B and hepatitis C virus. Overall, liver disease is the 4th 
leading cause of mortality, with 35.6 deaths per 100,000 persons 
in South Korea.18 
In South Korea, hepatitis A is classified as group 1 communica-
ble disease (water/foodborne disease) by nationally notifiable in-
fectious diseases. Every case identified is reported to the Centers 
for Disease Control & Prevention in South Korea through a man-
datory surveillance system. National vaccination program is also 
implemented for children. Hepatitis B is classified as group 2 com-
municable disease. National vaccination program for children and 
national prenatal hepatitis B prevention program are implement-
ed. Hepatitis C is classified as ‘designated communicable disease’, 
and sentinel surveillance has been done. Selected health care 
centers report every case of hepatitis C in sentinel surveillance 
system. Recently, hepatitis C has been re-classified as group 3 
communicable diseases. Mandatory surveillance system for every 
case is going to be implemented (Table 4). Detailed strategy for 
hepatitis A, hepatitis B and hepatitis C control in South Korea will 
be discussed separately in another review. There are no nation-
wide control programs for HEV or HDV. There are no nationwide 
programs for chronic hepatitis B patients yet.   
One limitation of viral hepatitis control program in South Korea 
is that there is no control center. Currently, five independent parts 
at Centers for Disease Control & Prevention are involved in man-
aging viral hepatitis (Table 5). To achieve the goal of viral hepatitis 
elimination by 2030 in South Korea, establishment of an indepen-
dent ‘viral hepatitis sector’ in Centers for Disease Control & Pre-
vention is needed to organize and execute comprehensive strategy 
for the management of viral hepatitis. 
Table 5. Current national organization involved in viral hepatitis control in South Korea (year 2016)
Hepatitis A Hepatitis B Hepatitis C
Division of infectious disease 
surveillance
Epidemiological investigation for 
outbreak
Epidemiological investigation for 
outbreak
Division of infectious disease 
control
Analysis of all reported cases of 
acute hepatitis A
Analysis of all reported cases of 
acute hepatitis B
Analysis of reported cases of 
hepatitis C from sentinel 
surveillance → analysis of all 
reported cases*
Division of VPD control and NIP National vaccination program for 
children
National vaccination program for 
children
National prenatal hepatitis B 
prevention program
Division of HIV/AIDS and TB 
control
Genotype evaluation in Outbreak 
investigation
Division of enteric diseases Research of viral hepatitis
*Changed in year 2016. 
Table 4. Current national strategy to monitor viral hepatitis in South Korea (year 2016)
Hepatitis A Hepatitis B Hepatitis C
Classification by the law Group 1 Group 2 Designated → Group 3*
Monitoring of cases All cases of acute hepatitis A All cases of acute hepatitis B Sentinel surveillance of newly identified 
hepatitis C infection → All cases*
National effort National vaccination program 
for children
National vaccination program for 
children
National prenatal hepatitis B 
prevention program
None
*Changed in year 2016. 
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SUMMARY 
Viral hepatitis is a huge burden worldwide as well as in South 
Korea. In response to WHO call to an action, South Korea must 
also prepare specific strategy to control viral hepatitis and stop vi-
ral hepatitis transmission. In this mini-series, current status and 
strategy for viral hepatitis are discussed in more details for hepati-
tis A, hepatitis B, and hepatitis C. This can help us achieve the 
goal of eliminating viral hepatitis as a public health threat by 
2030 in South Korea. 
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